Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully delivered the second preclinical candidate compound (PCC) in its collaboration with Fosun Pharma in June 2024, a potential innovative therapeutic using synthetic lethal strategy for the treatment of solid tumors.
TMS for Psych Disorders Poses Little Threat to Implanted Cardiac Devices
An electromagnetic therapy for depression shouldn’t damage a person’s pre-existing implantable cardioverter-defibrillator (ICD), multiple experiments indicated. There was a low risk of ICD damage or
January 5, 2024